The primary benefit of the BPCA is the increased volume of research on medications used in children, leading to better-informed prescribing practices. This helps in reducing the risks associated with off-label drug use in pediatric populations. Additionally, the BPCA has fostered the development of new pediatric formulations and dosing guidelines, which are critical for ensuring that children receive the most appropriate treatment.
